Protalix BioTherapeutics (PLX) Depreciation & Amortization (CF) (2010 - 2026)
Protalix BioTherapeutics' quarterly Depreciation & Amortization (CF) came in at $404000.0 in Q1 2026, up 16.76% year-on-year from $346000.0 in Q1 2025, and up 4.39% quarter-over-quarter from $387000.0 in Q4 2025.
Protalix BioTherapeutics has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $404000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 16.76% year-over-year to $404000.0; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 14.68% YoY), and the FY2025 full-year result was $1.5 million, up 12.35% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $404000.0, up from $387000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $404000.0 in Q1 2026, with the low at $268000.0 in Q2 2022.
- Average Depreciation & Amortization (CF) over 5 years is $321411.8, with a median of $319000.0 recorded in 2024.
- Year-over-year, Depreciation & Amortization (CF) decreased 6.94% in 2022 and rose 16.76% in 2026.
- Tracing PLX's Depreciation & Amortization (CF) over 5 years: stood at $289000.0 in 2022, then climbed by 8.3% to $313000.0 in 2023, then advanced by 6.71% to $334000.0 in 2024, then climbed by 15.87% to $387000.0 in 2025, then increased by 4.39% to $404000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $404000.0 (Q1 2026), $387000.0 (Q4 2025), and $372000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 404,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 404,000.00 |
| Mar 31, 2026 | 404,000.00 |
| Dec 31, 2025 | 387,000.00 |
| Dec 31, 2025 | 387,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Jun 30, 2025 | 360,000.00 |
| Jun 30, 2025 | 360,000.00 |
| Mar 31, 2025 | 346,000.00 |
| Mar 31, 2025 | 346,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Sep 30, 2024 | 329,000.00 |
| Sep 30, 2024 | 329,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Mar 31, 2024 | 322,000.00 |
| Mar 31, 2024 | 322,000.00 |
| Dec 31, 2023 | 313,000.00 |
| Dec 31, 2023 | 313,000.00 |
| Sep 30, 2023 | 305,000.00 |
| Sep 30, 2023 | 305,000.00 |
| Jun 30, 2023 | 293,000.00 |
| Jun 30, 2023 | 293,000.00 |
| Mar 31, 2023 | 280,000.00 |
| Mar 31, 2023 | 280,000.00 |
| Dec 31, 2022 | 289,000.00 |
| Dec 31, 2022 | 289,000.00 |
| Sep 30, 2022 | 273,000.00 |
| Sep 30, 2022 | 273,000.00 |
| Jun 30, 2022 | 268,000.00 |
| Jun 30, 2022 | 268,000.00 |
| Mar 31, 2022 | 270,000.00 |
| Mar 31, 2022 | 270,000.00 |
| Dec 31, 2021 | 259,000.00 |
| Dec 31, 2021 | 259,000.00 |
| Sep 30, 2021 | 285,000.00 |
| Sep 30, 2021 | 285,000.00 |
| Jun 30, 2021 | 288,000.00 |
| Jun 30, 2021 | 288,000.00 |
| Mar 31, 2021 | 286,000.00 |
| Mar 31, 2021 | 286,000.00 |
| Dec 31, 2020 | 289,000.00 |
| Dec 31, 2020 | 289,000.00 |
| Sep 30, 2020 | 301,000.00 |
| Sep 30, 2020 | 301,000.00 |
| Jun 30, 2020 | 334,000.00 |
| Jun 30, 2020 | 334,000.00 |
| Mar 31, 2020 | 376,000.00 |
| Mar 31, 2020 | 376,000.00 |
| Dec 31, 2019 | 395,000.00 |
| Dec 31, 2019 | 395,000.00 |
| Sep 30, 2019 | 421,000.00 |
| Sep 30, 2019 | 421,000.00 |
| Jun 30, 2019 | 379,000.00 |
| Jun 30, 2019 | 379,000.00 |
| Mar 31, 2019 | 405,000.00 |
| Mar 31, 2019 | 405,000.00 |
| Dec 31, 2018 | 414,000.00 |
| Dec 31, 2018 | 414,000.00 |
| Sep 30, 2018 | 411,000.00 |
| Sep 30, 2018 | 411,000.00 |
| Jun 30, 2018 | 416,000.00 |
| Jun 30, 2018 | 416,000.00 |
| Mar 31, 2018 | 430,000.00 |
| Mar 31, 2018 | 430,000.00 |
| Dec 31, 2017 | 451,000.00 |
| Dec 31, 2017 | 451,000.00 |
| Sep 30, 2017 | 483,000.00 |
| Sep 30, 2017 | 483,000.00 |
| Jun 30, 2017 | 494,000.00 |
| Jun 30, 2017 | 494,000.00 |
| Mar 31, 2017 | 492,000.00 |
| Mar 31, 2017 | 492,000.00 |
| Dec 31, 2016 | 494,000.00 |
| Dec 31, 2016 | 494,000.00 |
| Sep 30, 2016 | 483,000.00 |
| Sep 30, 2016 | 483,000.00 |
| Jun 30, 2016 | 490,000.00 |
| Jun 30, 2016 | 490,000.00 |
| Mar 31, 2016 | 516,000.00 |
| Mar 31, 2016 | 516,000.00 |
| Dec 31, 2015 | 559,000.00 |
| Dec 31, 2015 | 559,000.00 |
| Sep 30, 2015 | 588,000.00 |
| Sep 30, 2015 | 588,000.00 |
| Jun 30, 2015 | 607,000.00 |
| Jun 30, 2015 | 607,000.00 |
| Mar 31, 2015 | 616,000.00 |
| Mar 31, 2015 | 616,000.00 |
| Mar 31, 2014 | 828,000.00 |
| Mar 31, 2014 | 828,000.00 |
| Dec 31, 2013 | 850,000.00 |
| Dec 31, 2013 | 850,000.00 |
| Sep 30, 2013 | 871,000.00 |
| Sep 30, 2013 | 871,000.00 |
| Jun 30, 2013 | 892,000.00 |
| Jun 30, 2013 | 892,000.00 |
| Mar 31, 2013 | 926,000.00 |
| Mar 31, 2013 | 926,000.00 |
| Dec 31, 2012 | 920,000.00 |
| Dec 31, 2012 | 920,000.00 |
| Sep 30, 2012 | 912,000.00 |
| Sep 30, 2012 | 912,000.00 |
| Jun 30, 2012 | 930,000.00 |
| Jun 30, 2012 | 930,000.00 |
| Mar 31, 2012 | 930,000.00 |
| Mar 31, 2012 | 930,000.00 |
| Dec 31, 2011 | 933,000.00 |
| Dec 31, 2011 | 933,000.00 |
| Sep 30, 2011 | 897,000.00 |
| Sep 30, 2011 | 897,000.00 |
| Jun 30, 2011 | 923,000.00 |
| Jun 30, 2011 | 923,000.00 |
| Mar 31, 2011 | 878,000.00 |
| Mar 31, 2011 | 878,000.00 |
| Dec 31, 2010 | 889,000.00 |
| Dec 31, 2010 | 889,000.00 |
| Sep 30, 2010 | 789,000.00 |
| Sep 30, 2010 | 789,000.00 |